To our knowledge such a combination was not suggested in breast cancer before and recent combinatory treatment focused on combining Usp7 inhibition with chemotherapeutics 116, PARP-inhibitors 117,118, Notch1 pathway inhibitors 104 or proteasome-inhibitors 119 in different cancer entities, but not in breast cancer. Here, USP7 is linked to cancer.